An overview cost-utility analysis of prostate cancer screening.

I. M. Thompson, S. A. Optenberg

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The value of prostate cancer screening remains controversial because of the high prevalence of the disease and the fact that many tumors detected through screening are not destined to lead to morbidity or mortality, rendering treatment unnecessary. An ongoing NCI-sponsored screening trial may eventually put an end to the controversy. However, in the meantime, cost-utility estimates suggest that the cost per crude and quality-adjusted life year gained from prostate cancer screening and treatment ranges from $8,400 to $23,100 (with an estimated 1 to 2.68 QALYs gained from screening and treatment), and that these estimates are actually lower than, or well within the range of, the costs of many commonly accepted medical interventions, including screening mammography in women under age 50 ($232,000) and treatment of hypertension with captopril ($82,600) or hydrochlorothiazide ($23,500). Thus, we conclude that prostate cancer screening may indeed be cost effective and should be offered to men in the at-risk age range.

Original languageEnglish (US)
Pages (from-to)141-145
Number of pages5
JournalOncology (Williston Park, N.Y.)
Volume9
Issue number11 Suppl
StatePublished - Nov 1995

Fingerprint

Early Detection of Cancer
Cost-Benefit Analysis
Prostatic Neoplasms
Costs and Cost Analysis
Quality-Adjusted Life Years
Hydrochlorothiazide
Captopril
Mammography
Therapeutics
Hypertension
Morbidity
Mortality
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Thompson, I. M., & Optenberg, S. A. (1995). An overview cost-utility analysis of prostate cancer screening. Oncology (Williston Park, N.Y.), 9(11 Suppl), 141-145.

An overview cost-utility analysis of prostate cancer screening. / Thompson, I. M.; Optenberg, S. A.

In: Oncology (Williston Park, N.Y.), Vol. 9, No. 11 Suppl, 11.1995, p. 141-145.

Research output: Contribution to journalArticle

Thompson, IM & Optenberg, SA 1995, 'An overview cost-utility analysis of prostate cancer screening.', Oncology (Williston Park, N.Y.), vol. 9, no. 11 Suppl, pp. 141-145.
Thompson, I. M. ; Optenberg, S. A. / An overview cost-utility analysis of prostate cancer screening. In: Oncology (Williston Park, N.Y.). 1995 ; Vol. 9, No. 11 Suppl. pp. 141-145.
@article{ab72f45242454fcb94386b968bb8faa5,
title = "An overview cost-utility analysis of prostate cancer screening.",
abstract = "The value of prostate cancer screening remains controversial because of the high prevalence of the disease and the fact that many tumors detected through screening are not destined to lead to morbidity or mortality, rendering treatment unnecessary. An ongoing NCI-sponsored screening trial may eventually put an end to the controversy. However, in the meantime, cost-utility estimates suggest that the cost per crude and quality-adjusted life year gained from prostate cancer screening and treatment ranges from $8,400 to $23,100 (with an estimated 1 to 2.68 QALYs gained from screening and treatment), and that these estimates are actually lower than, or well within the range of, the costs of many commonly accepted medical interventions, including screening mammography in women under age 50 ($232,000) and treatment of hypertension with captopril ($82,600) or hydrochlorothiazide ($23,500). Thus, we conclude that prostate cancer screening may indeed be cost effective and should be offered to men in the at-risk age range.",
author = "Thompson, {I. M.} and Optenberg, {S. A.}",
year = "1995",
month = "11",
language = "English (US)",
volume = "9",
pages = "141--145",
journal = "ONCOLOGY (United States)",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "11 Suppl",

}

TY - JOUR

T1 - An overview cost-utility analysis of prostate cancer screening.

AU - Thompson, I. M.

AU - Optenberg, S. A.

PY - 1995/11

Y1 - 1995/11

N2 - The value of prostate cancer screening remains controversial because of the high prevalence of the disease and the fact that many tumors detected through screening are not destined to lead to morbidity or mortality, rendering treatment unnecessary. An ongoing NCI-sponsored screening trial may eventually put an end to the controversy. However, in the meantime, cost-utility estimates suggest that the cost per crude and quality-adjusted life year gained from prostate cancer screening and treatment ranges from $8,400 to $23,100 (with an estimated 1 to 2.68 QALYs gained from screening and treatment), and that these estimates are actually lower than, or well within the range of, the costs of many commonly accepted medical interventions, including screening mammography in women under age 50 ($232,000) and treatment of hypertension with captopril ($82,600) or hydrochlorothiazide ($23,500). Thus, we conclude that prostate cancer screening may indeed be cost effective and should be offered to men in the at-risk age range.

AB - The value of prostate cancer screening remains controversial because of the high prevalence of the disease and the fact that many tumors detected through screening are not destined to lead to morbidity or mortality, rendering treatment unnecessary. An ongoing NCI-sponsored screening trial may eventually put an end to the controversy. However, in the meantime, cost-utility estimates suggest that the cost per crude and quality-adjusted life year gained from prostate cancer screening and treatment ranges from $8,400 to $23,100 (with an estimated 1 to 2.68 QALYs gained from screening and treatment), and that these estimates are actually lower than, or well within the range of, the costs of many commonly accepted medical interventions, including screening mammography in women under age 50 ($232,000) and treatment of hypertension with captopril ($82,600) or hydrochlorothiazide ($23,500). Thus, we conclude that prostate cancer screening may indeed be cost effective and should be offered to men in the at-risk age range.

UR - http://www.scopus.com/inward/record.url?scp=0029397198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029397198&partnerID=8YFLogxK

M3 - Article

C2 - 8608045

AN - SCOPUS:0029397198

VL - 9

SP - 141

EP - 145

JO - ONCOLOGY (United States)

JF - ONCOLOGY (United States)

SN - 0890-9091

IS - 11 Suppl

ER -